Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Read More…
Industry, Sector and Symbol
Industry Computer integrated systems design
Sub-IndustryN/A
SectorComputer and Technology
Phone661-723-7723
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$29.67 million
Profitability
Miscellaneous
Employees93
Next Earnings Date11/13/2019 (Estimated)
OptionableOptionable
Simulations Plus (NASDAQ:SLP) Frequently Asked Questions
What is Simulations Plus' stock symbol?
Simulations Plus trades on the NASDAQ under the ticker symbol "SLP."
How often does Simulations Plus pay dividends? What is the dividend yield for Simulations Plus?
Simulations Plus declared a quarterly dividend on Wednesday, July 10th. Shareholders of record on Thursday, July 25th will be paid a dividend of $0.06 per share on Thursday, August 1st. This represents a $0.24 annualized dividend and a yield of 0.69%. The ex-dividend date of this dividend is Wednesday, July 24th. View Simulations Plus' Dividend History.
How were Simulations Plus' earnings last quarter?
Simulations Plus, Inc. (NASDAQ:SLP) released its earnings results on Tuesday, July, 10th. The technology company reported $0.13 EPS for the quarter, beating analysts' consensus estimates of $0.12 by $0.01. The technology company had revenue of $8.55 million for the quarter, compared to analysts' expectations of $7.86 million. Simulations Plus had a return on equity of 23.48% and a net margin of 24.09%. View Simulations Plus' Earnings History.
When is Simulations Plus' next earnings date?
What is the consensus analysts' recommendation for Simulations Plus?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Simulations Plus in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Simulations Plus.
Has Simulations Plus been receiving favorable news coverage?
News articles about SLP stock have been trending somewhat negative on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Simulations Plus earned a news impact score of -1.4 on InfoTrie's scale. They also assigned headlines about the technology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Simulations Plus.
Are investors shorting Simulations Plus?
Simulations Plus saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 576,000 shares, an increase of 15.3% from the August 30th total of 499,600 shares. Based on an average trading volume of 179,200 shares, the short-interest ratio is currently 3.2 days. Currently, 4.7% of the company's stock are sold short. View Simulations Plus' Current Options Chain.
Who are some of Simulations Plus' key competitors?
Some companies that are related to Simulations Plus include Scientific Games (SGMS), Allscripts Healthcare Solutions (MDRX), NetScout Systems (NTCT), Sykes Enterprises (SYKE), Ebix (EBIX), Nextgen Healthcare (NXGN), Agilysys (AGYS), Ribbon Communications (RBBN), Onespan (OSPN), Tufin Software Technologies (TUFN), Digimarc (DMRC), Unisys (UIS), Aerohive Networks (HIVE), Asure Software (ASUR) and Pareteum (TEUM).
What other stocks do shareholders of Simulations Plus own?
Who are Simulations Plus' key executives?
Simulations Plus' management team includes the folowing people:
- Mr. Walter S. Woltosz, Co-Founder & Chairman (Age 74)
- Mr. Shawn M. O'Connor, Chief Exec. Officer (Age 59)
- Mr. John R. Kneisel, Chief Financial Officer (Age 61)
- Dr. Thaddeus Henry Grasela Jr., Pharm.D., PharmD, Ph.D., Pres Buffalo Division, Director of Simulations Plus & Director (Age 65)
- Mr. John Anthony DiBella, Pres of the Lancaster Division (Age 39)
How do I buy shares of Simulations Plus?
Shares of SLP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Simulations Plus' stock price today?
One share of SLP stock can currently be purchased for approximately $34.79.
How big of a company is Simulations Plus?
Simulations Plus has a market capitalization of $609.87 million and generates $29.67 million in revenue each year. The technology company earns $8.93 million in net income (profit) each year or $0.50 on an earnings per share basis. Simulations Plus employs 93 workers across the globe.View Additional Information About Simulations Plus.
What is Simulations Plus' official website?
How can I contact Simulations Plus?
Simulations Plus' mailing address is 42505 10TH STREET WEST, LANCASTER CA, 93534. The technology company can be reached via phone at 661-723-7723 or via email at [email protected]
MarketBeat Community Rating for Simulations Plus (NASDAQ SLP)
MarketBeat's community ratings are surveys of what our community members think about Simulations Plus and other stocks. Vote "Outperform" if you believe SLP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLP will underperform the S&P 500 over the long term. You may vote once every thirty days.
